Global Immunoglobulins Market to Reach USD 27.7 Billion by 2031, Growing at 6.2% CAGR

Author : kaustubh Ravan | Published On : 23 Apr 2026

The global immunoglobulins market was valued at USD 16.3 billion in 2022 and is projected to reach USD 27.7 billion by the end of 2031. This reflects a compound annual growth rate (CAGR) of 6.2% during the forecast period from 2023 to 2031. The market growth is driven by rising prevalence of immune deficiencies, autoimmune disorders, and increasing use of immunoglobulin therapies in neurological and chronic disease treatments, along with expanding healthcare access and advancements in biologic therapies.

Dive Deeper into Data: Get Your In-Depth Sample Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=52353

Market dynamics are currently centered on the "Home-Care Transition." Survey data from early 2026 indicates that over 82% of patients now prefer subcutaneous delivery over intravenous infusions, citing the autonomy of home administration and a reduced travel burden. This shift is being supported by insurers, as shifting patients to home settings can avoid the high costs of hospital admissions for severe infections—often exceeding US$ 122,000 per patient-year. However, the market remains highly sensitive to Plasma Supply Constraints. Because production is limited by the quantity of human plasma collected, vendors like CSL Behring and Grifols are aggressively expanding fractionation capacities and localized collection centers to mitigate supply-demand imbalances.

Technological innovation is pivoting toward Facilitated SCIg and Digital Monitoring. In 2025 and 2026, the regulatory clearance of therapies like HYQVIA for broader indications (including CIDP and secondary immunodeficiency) has paved the way for "facilitated" subcutaneous delivery, allowing for high-volume infusions that were previously only possible intravenously. A key trend in 2026 is the integration of wearable infusion devices and digital adherence tools, which allow clinicians to monitor patient compliance and serum biomarker levels remotely. Furthermore, advancements in recombinant and engineered antibodies are under development, aiming to provide products with extended half-lives and reduced systemic reactions.

The regional landscape is anchored by North America, which held a dominant market share of approximately 46% in 2025. The U.S. remains the largest single market, valued at US$ 11.6 billion, driven by high awareness and a patient-centric reimbursement system. However, Asia-Pacific is the fastest-growing region. Driven by rising healthcare spending in China and India and a significant increase in the diagnosis of primary immunodeficiency (PID), the region is scaling its domestic plasma fractionation infrastructure to reduce long-term dependency on imports.

Key Findings of the Market Report

Based on route of administration, IVIG holds the largest current revenue share, while SCIg is recording the fastest growth due to the patient preference for home-based therapy.
Primary Immunodeficiency Disease (PID) remains the leading application segment, accounting for approximately 26.3% of the market share in early 2026.
Neurological Applications (e.g., CIDP and Myasthenia Gravis) are the fastest-growing sub-sectors as more autoimmune indications receive guideline support for maintenance dosing.
Hospital Pharmacies account for the majority of distribution share (57.3%), but Specialty Pharmacies are capturing significant growth through home-care delivery models.

Global Market: Growth Drivers

Rising Prevalence of Autoimmune Disorders: Growing incidences of CIDP, ITP, and Kawasaki disease are driving steady demand for long-term antibody replacement.
Aging Global Population: Older demographics are more susceptible to secondary immunodeficiencies, increasing the long-term patient pool for Ig therapies.
Advancements in Personalized Medicine: AI-driven diagnostic tools are helping clinicians stratify patients for the most effective delivery routes and dosing schedules.
Government Support for Rare Diseases: Expanded reimbursement and national screening programs in emerging markets are identifying previously undiagnosed PID patients.

Global Market: Key Players

Market leadership is highly concentrated, with the "Big Three" (CSL, Takeda, and Grifols) controlling nearly 75% of the global market through massive infrastructure investments.

CSL Behring (CSL Ltd.)
Takeda Pharmaceutical Company Limited
Grifols S.A.
Octapharma AG
Kedrion Biopharma
Baxter International Inc.
GC Biopharma (ALYGLO)
ADMA Biologics, Inc.
China Biologic Products Holdings
LFB Group

Global Market: Segmentation

By Route of Administration

Intravenous Immunoglobulin (IVIG)
Subcutaneous Immunoglobulin (SCIg)
Intramuscular Immunoglobulin (IMIG)

By Application

Primary Immunodeficiency (PID)
Secondary Immunodeficiency (SID)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immune Thrombocytopenic Purpura (ITP)
Guillain-Barre Syndrome
Kawasaki Disease

By Product Type

IgG (Most common)
IgA
IgM
IgE
IgD

By End-User

Hospitals and Clinics
Homecare Settings
Ambulatory Surgical Centers (ASCs)

Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=52353&ltype=S

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com